Hepatitis B treatment vs Hepatitis C treatment
How to tell Hepatitis B treatment and Hepatitis C treatment apart when a board question makes them look alike.
Step 2 CK pairs are in open beta while clinical review finishes. Spot an issue? Tell us.
HBV treatment is usually indefinite viral suppression, while HCV treatment is a time-limited curative DAA course.
Side by side
Chronic hepatitis B with elevated HBV DNA and active inflammation is managed with long-term nucleos(t)ide suppression.
Chronic hepatitis C is treated with finite direct-acting antiviral regimens that achieve virologic cure in most patients.
HBV persists as covalently closed circular DNA, so therapy usually suppresses replication rather than eradicating the virus.
HCV replication can be eradicated with combination direct-acting antivirals targeting NS3, NS5A, and NS5B pathways.
Treatment candidates include HBV DNA above 2000 IU/mL with ALT elevation or significant fibrosis, and first-line agents are tenofovir or entecavir with serial HBV DNA and ALT monitoring every 3 to 6 months.
HCV RNA positivity confirms active infection, and pan-genotypic regimens such as glecaprevir-pibrentasvir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks are chosen based on cirrhosis and prior treatment status.
The trap
Clinicians may apply HBV-style lifelong suppression to HCV or stop HBV therapy too early after biochemical improvement. The resolving clue is viral biology: HBV persists in hepatocyte nuclei, HCV can be eradicated.
The repair move
Next best step: start first-line HBV suppression with tenofovir disoproxil 300 mg daily or entecavir 0.5 mg daily and continue long term with HBV DNA, ALT, and renal monitoring. For chronic HCV, select a direct-acting antiviral regimen such as glecaprevir-pibrentasvir 3 tablets daily for 8 weeks in noncirrhotic treatment-naive patients, then confirm sustained virologic response at 12 weeks after completion.
Try a free question
CoreA 39-year-old woman with chronic hepatitis B has ALT 98 U/L and HBV DNA 2.8 x 10^4 IU/mL on repeat testing. BP 124/76 mm Hg, HR 82/min, temp 37.1 C, and fibrosis staging shows F2 disease. What is the next best step in management?
Show answer and explanation
Answer: A. Start tenofovir therapy with long-term monitoring. Active chronic HBV with elevated viral load and fibrosis should be treated with first-line long-term nucleos(t)ide suppression.
Why the other choices are tempting
- B. Finite short-course treatment is typical for HCV, not standard for active HBV with fibrosis.
- C. Untreated active HBV with fibrosis risks progression to cirrhosis and carcinoma.
- D. Ribavirin alone is not a recommended HBV strategy.
- E. Single-dose interferon and discharge is not appropriate chronic HBV care.
Flashcards
Tap a card to flip it.
What treatment duration difference is most important between chronic HBV and chronic HCV?
HBV therapy is typically long-term suppression, while HCV therapy is usually a finite curative DAA course.
Which first-line oral agents are commonly used for chronic hepatitis B suppression?
Tenofovir or entecavir are preferred first-line nucleos(t)ide analogs for chronic HBV.
Quick answers
What is the fastest way to tell Hepatitis B treatment from Hepatitis C treatment?
HBV treatment is usually indefinite viral suppression, while HCV treatment is a time-limited curative DAA course.
What is the key clue for Hepatitis B treatment?
Chronic hepatitis B with elevated HBV DNA and active inflammation is managed with long-term nucleos(t)ide suppression.
What is the key clue for Hepatitis C treatment?
Chronic hepatitis C is treated with finite direct-acting antiviral regimens that achieve virologic cure in most patients.
What is the common trap with Hepatitis B treatment vs Hepatitis C treatment?
Clinicians may apply HBV-style lifelong suppression to HCV or stop HBV therapy too early after biochemical improvement. The resolving clue is viral biology: HBV persists in hepatocyte nuclei, HCV can be eradicated.